OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Sep 2019 to Sep 2024
OraSure Technologies, Inc. (NASDAQ:OSUR) announced that it has received
a complaint from Inverness Medical Innovations, Inc. (AMEX:IMA),
Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc.
(NYSE:CHD), filed in the United States District Court for the District
of New Jersey, alleging that the manufacture and sale of the Company’s
OraQuick ADVANCE®
Rapid HIV-1/2 Antibody Test infringes U.S. Patent No. 6,485,982. OraSure
Technologies believes that none of its products, including the OraQuick ADVANCE®
Test, infringe the patent or other intellectual property rights of any
party. The Company also believes that the asserted patent is invalid and
intends to defend this lawsuit vigorously.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid
specimen collection devices using proprietary oral fluid technologies,
diagnostic products including immunoassays and other in vitro
diagnostic tests, and other medical devices. These products are sold in
the United States as well as internationally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, distributors, government agencies,
physicians’ offices, and commercial and
industrial entities.
OraSure Technologies is the leading supplier of oral-fluid collection
devices and assays to the public health and life insurance markets for
the detection of antibodies to HIV. In addition, the Company supplies
oral-fluid testing solutions for drugs of abuse testing. For more
information on the Company, please go to www.orasure.com.